Immunotherapy Biomarkers. Moving Beyond PDL1 to Determine Which Patients Are Most Likely to Benefit

Direct from ASCO 2017<br />Highlights and New Approaches in Head and Neck Cancer<br /><a target='_blank' href='http://cancerGRACE.org/'>http://cancerGRACE.org/...</a> Author: cancergrace Added: 08/09/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts